IN2015DN03219A - - Google Patents
Info
- Publication number
- IN2015DN03219A IN2015DN03219A IN3219DEN2015A IN2015DN03219A IN 2015DN03219 A IN2015DN03219 A IN 2015DN03219A IN 3219DEN2015 A IN3219DEN2015 A IN 3219DEN2015A IN 2015DN03219 A IN2015DN03219 A IN 2015DN03219A
- Authority
- IN
- India
- Prior art keywords
- pridopidine
- laquinimod
- treating
- neurodegenerative disorder
- provides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Mechanical Engineering (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261706695P | 2012-09-27 | 2012-09-27 | |
US201361879004P | 2013-09-17 | 2013-09-17 | |
PCT/US2013/062482 WO2014052933A1 (en) | 2012-09-27 | 2013-09-27 | Laquinimod and pridopidine for treating neurodegenerative disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2015DN03219A true IN2015DN03219A (zh) | 2015-10-02 |
Family
ID=50339469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN3219DEN2015 IN2015DN03219A (zh) | 2012-09-27 | 2013-09-27 |
Country Status (13)
Country | Link |
---|---|
US (7) | US20140088140A1 (zh) |
EP (1) | EP2900330A4 (zh) |
CN (1) | CN104902958A (zh) |
AU (1) | AU2013323131A1 (zh) |
BR (1) | BR112015006623A2 (zh) |
CA (1) | CA2884781A1 (zh) |
EA (1) | EA201590655A8 (zh) |
HK (2) | HK1211525A1 (zh) |
IL (1) | IL237742A0 (zh) |
IN (1) | IN2015DN03219A (zh) |
MX (1) | MX2015003608A (zh) |
WO (1) | WO2014052933A1 (zh) |
ZA (1) | ZA201502600B (zh) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
WO2008127188A1 (en) * | 2007-04-12 | 2008-10-23 | Allbay Ab | N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles |
US20130197031A1 (en) | 2010-09-03 | 2013-08-01 | IVAX International GmbH | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
EP2753603B1 (en) | 2011-09-07 | 2017-06-21 | Teva Pharmaceuticals International GmbH | Polymorphic form of pridopidine hydrochloride |
UY34503A (es) | 2011-12-08 | 2013-07-31 | Ivax Int Gmbh | ?sal de bromhidrato de pridopidina? |
US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
ES2879631T3 (es) | 2013-06-21 | 2021-11-22 | Prilenia Neurotherapeutics Ltd | Pridopidina para el tratamiento de la enfermedad de Huntington |
CA2933380A1 (en) * | 2013-12-20 | 2015-06-25 | Esther Lukasiewicz Hagai | Use of laquinimod to delay huntington's disease progression |
TW201613859A (en) * | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
CA2961187A1 (en) * | 2014-09-16 | 2016-03-24 | Teva Pharmaceuticals Industries Ltd. | Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod |
US9796673B2 (en) | 2014-12-22 | 2017-10-24 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
HUE060353T2 (hu) * | 2015-02-25 | 2023-02-28 | Prilenia Neurotherapeutics Ltd | Pridopidin alkalmazása memória javítására |
US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
US20170020854A1 (en) * | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
WO2017048457A1 (en) * | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
CA3151507C (en) | 2016-08-24 | 2024-05-28 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating functional decline |
WO2019010491A1 (en) * | 2017-07-07 | 2019-01-10 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | COMBINATIONS OF MEDICINES FOR THE PROTECTION AGAINST THE DEATH OF NEURONAL CELLS |
FI3668509T3 (fi) | 2017-08-14 | 2023-03-14 | Prilenia Neurotherapeutics Ltd | Menetelmä hoitaa amyotrofista lateraaliskleroosia pridopidiinilla |
CA3128250C (en) * | 2019-03-15 | 2024-01-16 | Michael Hayden | Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine |
MX2021015338A (es) * | 2019-06-12 | 2022-01-18 | Prilenia Neurotherapeutics Ltd | Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma. |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2528040T3 (es) * | 2007-06-18 | 2015-02-03 | A.Carlsson Research Ab | Uso de estabilizadores de dopamina |
CA2743717A1 (en) * | 2008-11-13 | 2010-05-20 | Link Medicine Corporation | Azaquinolinone derivatives and uses thereof |
JP5859438B2 (ja) * | 2009-08-10 | 2016-02-10 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドを用いたbdnf関連疾患の治療 |
WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
BR112013014061A2 (pt) * | 2010-12-07 | 2016-09-13 | Teva Pharma | uso de laquinimod para redução da fadiga, melhorando o estado fundicional e melhorando a qualidade de vida nos pacientes com esclerose múltipla |
-
2013
- 2013-09-27 MX MX2015003608A patent/MX2015003608A/es unknown
- 2013-09-27 EP EP13840841.4A patent/EP2900330A4/en not_active Withdrawn
- 2013-09-27 CN CN201380050913.8A patent/CN104902958A/zh active Pending
- 2013-09-27 IN IN3219DEN2015 patent/IN2015DN03219A/en unknown
- 2013-09-27 US US14/040,586 patent/US20140088140A1/en not_active Abandoned
- 2013-09-27 CA CA2884781A patent/CA2884781A1/en active Pending
- 2013-09-27 BR BR112015006623A patent/BR112015006623A2/pt active Search and Examination
- 2013-09-27 WO PCT/US2013/062482 patent/WO2014052933A1/en active Application Filing
- 2013-09-27 US US14/426,327 patent/US20150209346A1/en not_active Abandoned
- 2013-09-27 EA EA201590655A patent/EA201590655A8/ru unknown
- 2013-09-27 AU AU2013323131A patent/AU2013323131A1/en not_active Abandoned
-
2015
- 2015-03-15 IL IL237742A patent/IL237742A0/en unknown
- 2015-04-17 ZA ZA2015/02600A patent/ZA201502600B/en unknown
- 2015-12-15 HK HK15112317.4A patent/HK1211525A1/zh unknown
-
2016
- 2016-03-01 HK HK16102362.8A patent/HK1214553A1/zh unknown
-
2017
- 2017-07-20 US US15/655,580 patent/US20170319569A1/en not_active Abandoned
- 2017-11-02 US US15/801,703 patent/US20180133209A1/en not_active Abandoned
-
2018
- 2018-05-08 US US15/974,112 patent/US20180250285A1/en not_active Abandoned
- 2018-08-30 US US16/117,604 patent/US20180369228A1/en not_active Abandoned
- 2018-12-18 US US16/223,993 patent/US20190117639A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HK1211525A1 (zh) | 2016-05-27 |
AU2013323131A1 (en) | 2015-05-07 |
EA201590655A8 (ru) | 2016-07-29 |
CA2884781A1 (en) | 2014-04-03 |
CN104902958A (zh) | 2015-09-09 |
WO2014052933A1 (en) | 2014-04-03 |
EP2900330A1 (en) | 2015-08-05 |
US20190117639A1 (en) | 2019-04-25 |
US20180133209A1 (en) | 2018-05-17 |
IL237742A0 (en) | 2015-05-31 |
US20180369228A1 (en) | 2018-12-27 |
US20140088140A1 (en) | 2014-03-27 |
US20150209346A1 (en) | 2015-07-30 |
ZA201502600B (en) | 2016-06-29 |
HK1214553A1 (zh) | 2016-07-29 |
EA201590655A1 (ru) | 2015-12-30 |
MX2015003608A (es) | 2015-06-05 |
US20170319569A1 (en) | 2017-11-09 |
EP2900330A4 (en) | 2016-05-25 |
BR112015006623A2 (pt) | 2017-07-04 |
US20180250285A1 (en) | 2018-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2015DN03219A (zh) | ||
WO2014052935A3 (en) | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease | |
MX365835B (es) | Uso de akkermansia para tratar trastornos metabolicos. | |
MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
MX2018002990A (es) | Uso de la akkermansia pasteurizada para tratar trastornos metabolicos. | |
PH12014501560A1 (en) | Carbamate compounds and of making and using same | |
MY166014A (en) | Combination therapy methods for treating proliferative diseases | |
SG10201810888XA (en) | Compositions and methods comprising bupropion or related compounds and dextromethorphan | |
SG10201804552WA (en) | Nanoparticle compositions, formulations thereof, and uses therefor | |
MX2021005317A (es) | Composiciones y métodos para absorción transmucosa. | |
PH12016500296A1 (en) | Sodium channel modulators for the treatment of pain and diabetes | |
BR112012022552A2 (pt) | uso de fenoterol e de anélogos de fenoterol no tratamento de gliobastomas e astrocitomas | |
MX2015010296A (es) | Tratamiento de formas progresivas de esclerosis multiple con laquinimod. | |
MX2015012315A (es) | Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica. | |
MX2015000485A (es) | Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina. | |
PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
MX2016008027A (es) | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. | |
MX370451B (es) | Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi metil)-naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular. | |
MX2016001177A (es) | Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina. | |
MX2014013491A (es) | Metodos para mantener, tratar o mejorar la funcion cognitiva. | |
IN2013MU01155A (zh) | ||
IN2013MU01252A (zh) | ||
IN2013MU01154A (zh) | ||
IN2013MU01246A (zh) | ||
IN2013MU01244A (zh) |